<p>Thurston Springer Miller Herd  Titak Inc. 在最近向美國證券交易委員會（SEC）提交的文件中表示，在第三季度將其在 Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX - 免費報告) 的持倉降低了 91.2%。該基金在季度內出售了 2,487 股後，持有該製藥公司 240 股股票。根據其最近的 SEC 文件，Thurston Springer Miller Herd  Titak Inc. 在 Vertex Pharmaceuticals 的持股價值為 94,000 美元。</p>
<ul>
<li>Royalty Pharma 如何在沒有生物技術最大風險的情況下盈利</li>
</ul>
<p>其他機構投資者也對該公司的股份進行了增減。Costello Asset Management INC 在第二季度將其在 Vertex Pharmaceuticals 的股份增加了 3.6%。Costello Asset Management INC 目前持有 689 股該製藥公司的股票，價值 307,000 美元，此前在上個季度又購買了 24 股。Kovack Advisors Inc. 在第二季度將其在 Vertex Pharmaceuticals 的持股增加了 1.9%。Kovack Advisors Inc. 目前持有 1,280 股該製藥公司的股票，價值 570,000 美元，此前在該期間又購買了 24 股。Newman Dignan  Sheerar Inc. 在第二季度將其在 Vertex Pharmaceuticals 的股份增加了 3.3%。Newman Dignan  Sheerar Inc. 目前持有 786 股該製藥公司的股票，價值 350,000 美元，此前在上個季度又購買了 25 股。Eastern Bank 在第二季度將其在 Vertex Pharmaceuticals 的持股增加了 1.6%。Eastern Bank 目前持有 1,635 股該製藥公司的股票，價值 728,000 美元，此前在該期間又收購了 25 股。最後，Washington Trust Advisors Inc. 在第二季度將其在 Vertex Pharmaceuticals 的股份增加了 8.4%。Washington Trust Advisors Inc. 目前持有 323 股該製藥公司的股票，價值 144,000 美元，此前在上個季度又收購了 25 股。90.96% 的股票由對沖基金和其他機構投資者持有。</p>
<p>獲取 <strong>Vertex Pharmaceuticals</strong> 的提醒：</p>
<h2>內部人士下注</h2>
<p>在其他 Vertex Pharmaceuticals 的新聞中，執行副總裁 Charles F. Wagner, Jr. 於 12 月 3 日星期三出售了 14,000 股該公司的股票。股票以平均價格 456.00 美元出售，總交易額為 6,384,000.00 美元。出售後，該執行副總裁在公司持有 37,725 股，價值 17,202,600 美元。此交易代表其持股減少了 27.07%。該交易在向 SEC 提交的文件中披露，相關文件可通過此鏈接獲取。此外，董事長 Jeffrey M. Leiden 於 12 月 3 日星期三出售了 63,781 股公司的股票。股票以平均價格 449.20 美元出售，總價值為 28,650,425.20 美元。交易完成後，董事長持有 24,026 股公司的股票，價值 10,792,479.20 美元。該交易使其持股減少了 72.64%。該銷售的 SEC 文件提供了更多信息。在過去三個月中，內部人士出售了 151,073 股公司股票，價值 67,326,816 美元。0.20% 的股票由內部人士持有。</p>
<h2>Vertex Pharmaceuticals 股價下跌 1.2%</h2>
<ul>
<li>2025 年最佳生物技術股票</li>
</ul>
<p>VRTX 股票在星期四開盤價為 449.52 美元。該公司的 50 日移動平均線為 429.02 美元，200 日移動平均線為 425.79 美元。該股票的市值為 1,140.5 億美元，市盈率為 31.70，貝塔值為 0.32。Vertex Pharmaceuticals Incorporated 的 1 年最低價為 362.50 美元，1 年最高價為 519.68 美元。</p>
<p>Vertex Pharmaceuticals (NASDAQ:VRTX - 獲取免費報告) 最近於 11 月 3 日星期一發布了季度財報。該製藥公司報告季度每股收益為 4.80 美元，超出分析師一致預期的 4.58 美元，超出幅度為 0.22 美元。該業務在季度內的收入為 30.8 億美元，而分析師預期為 30.5 億美元。Vertex Pharmaceuticals 的淨利潤率為 31.35%，股本回報率為 23.51%。該業務的季度收入較去年同期增長了 11.0%。在去年同期，該公司每股收益為 4.38 美元。作為一個整體，賣方分析師預測 Vertex Pharmaceuticals Incorporated 在當前財政年度將發佈 15.63 美元的每股收益。</p>
<h2>分析師評級變動</h2>
<ul>
<li>MaxCyte：構建細胞和基因治療創新的未來</li>
</ul>
<p>幾位股票分析師最近對 VRTX 股票發表了看法。加拿大皇家銀行在 11 月 4 日的研究報告中將 Vertex Pharmaceuticals 的目標價從 423.00 美元下調至 415.00 美元，並對該公司給予了 “行業表現” 評級。摩根大通在 10 月 8 日的報告中將 Vertex Pharmaceuticals 的目標價從 517.00 美元上調至 530.00 美元，並給予該公司 “增持” 評級。Weiss Ratings 在 10 月 8 日的報告中重新發布了對 Vertex Pharmaceuticals 股票的 “持有（c+）” 評級。花旗集團在 10 月 2 日的研究報告中將 Vertex Pharmaceuticals 股票的目標價從 550.00 美元上調至 575.00 美元，並給予該公司 “買入” 評級。最後，華爾街禪在 8 月 22 日的報告中將 Vertex Pharmaceuticals 的評級從 “強烈買入” 下調至 “買入”。三位投資分析師對該股票給予了強烈買入評級，十五位給予了買入評級，十位對該公司的股票給予了持有評級。根據 MarketBeat 的數據，該股票的共識評級為 “適度買入”，平均目標價為 498.42 美元。</p>
<p><strong>獲取我們最新的 VRTX 股票報告</strong></p>
<h2>Vertex Pharmaceuticals 公司簡介</h2>
<p>（免費報告）</p>
<p>Vertex Pharmaceuticals Incorporated 是一家生物技術公司，專注於開發和商業化治療囊性纖維化（CF）的療法。它為至少有一個 F508del 突變、年齡在 2 歲或以上的 CF 患者銷售 TRIKAFTA/KAFTRIO；為年齡在 6 歲或以上的 CF 患者銷售 SYMDEKO/SYMKEVI；為 1 歲或以上的 CF 患者銷售 ORKAMBI；以及為 1 歲或以上的 CF 患者銷售 KALYDECO，適用於 ivacaftor 治療。</p>
<h2>推薦故事</h2>
<ul>
<li>我們更看好的五隻股票，勝過 Vertex Pharmaceuticals</li>
<li>FAANG 股票是什麼？它們是好的投資嗎？</li>
<li>在上漲 35% 後，分析師關注銅業巨頭 Freeport 的更多上漲空間</li>
<li>能源和石油股票解析</li>
<li>為什麼 SpaceX 的 IPO 可能成為 GOOGL 股票的主要催化劑</li>
<li>市值計算器：如何計算市值</li>
<li>Upwork 能否維持復甦？看漲和看跌的理由</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VlJUWA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VlJUWA"/></p>
<p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，旨在為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資$1,000 在 Vertex Pharmaceuticals 嗎？</h2>
<p>在考慮 Vertex Pharmaceuticals 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄建議客户現在購買的股票，以便在更廣泛的市場注意到之前……而 Vertex Pharmaceuticals 並不在名單上。</p>
<p>雖然 Vertex Pharmaceuticals 目前在分析師中獲得了中等買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

福泰制藥

<p>Thurston Springer Miller Herd & Titak Inc. 在第三季度大幅減少了對 Vertex Pharmaceuticals 的持股，減持幅度達到 91.2%，出售了 2,487 股。該基金目前持有 240 股，市值為 94,000 美元。其他機構投資者也對 Vertex 調整了他們的持倉，其中一些增加了持股。包括執行副總裁 Charles F. Wagner, Jr. 和董事長 Jeffrey M. Leiden 在內的內部人士也出售了股份。Vertex 的股票開盤價為 449.52 美元，市值為 1,140.5 億美元。該公司報告了強勁的季度收益，超出了分析師的預期</p>

<p>Thurston Springer Miller Herd &amp; Titak Inc. lowered its position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX - Free Report) by 91.2% in the 3rd quarter, according to the company in its most recent filing with the SEC. The fund owned 240 shares of the pharmaceutical company's stock after selling 2,487 shares during the quarter. Thurston Springer Miller Herd &amp; Titak Inc.'s holdings in Vertex Pharmaceuticals were worth $94,000 as of its most recent SEC filing.</p>
<div class="lb-trans"><p>Thurston Springer Miller Herd  Titak Inc. 在最近向美國證券交易委員會（SEC）提交的文件中表示，在第三季度將其在 Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX - 免費報告) 的持倉降低了 91.2%。該基金在季度內出售了 2,487 股後，持有該製藥公司 240 股股票。根據其最近的 SEC 文件，Thurston Springer Miller Herd  Titak Inc. 在 Vertex Pharmaceuticals 的持股價值為 94,000 美元。</p>
</div><ul>
<li>How Royalty Pharma Prints Cash Without Biotech's Biggest Risks</li>
</ul>
<div class="lb-trans"><ul>
<li>Royalty Pharma 如何在沒有生物技術最大風險的情況下盈利</li>
</ul>
</div><p>Other institutional investors have also added to or reduced their stakes in the company. Costello Asset Management INC increased its stake in shares of Vertex Pharmaceuticals by 3.6% in the second quarter. Costello Asset Management INC now owns 689 shares of the pharmaceutical company's stock worth $307,000 after purchasing an additional 24 shares in the last quarter. Kovack Advisors Inc. boosted its holdings in Vertex Pharmaceuticals by 1.9% in the 2nd quarter. Kovack Advisors Inc. now owns 1,280 shares of the pharmaceutical company's stock worth $570,000 after buying an additional 24 shares during the period. Newman Dignan &amp; Sheerar Inc. grew its stake in Vertex Pharmaceuticals by 3.3% in the 2nd quarter. Newman Dignan &amp; Sheerar Inc. now owns 786 shares of the pharmaceutical company's stock valued at $350,000 after buying an additional 25 shares in the last quarter. Eastern Bank raised its holdings in Vertex Pharmaceuticals by 1.6% during the 2nd quarter. Eastern Bank now owns 1,635 shares of the pharmaceutical company's stock valued at $728,000 after acquiring an additional 25 shares during the period. Finally, Washington Trust Advisors Inc. lifted its position in shares of Vertex Pharmaceuticals by 8.4% during the second quarter. Washington Trust Advisors Inc. now owns 323 shares of the pharmaceutical company's stock worth $144,000 after acquiring an additional 25 shares in the last quarter. 90.96% of the stock is owned by hedge funds and other institutional investors.</p>
<div class="lb-trans"><p>其他機構投資者也對該公司的股份進行了增減。Costello Asset Management INC 在第二季度將其在 Vertex Pharmaceuticals 的股份增加了 3.6%。Costello Asset Management INC 目前持有 689 股該製藥公司的股票，價值 307,000 美元，此前在上個季度又購買了 24 股。Kovack Advisors Inc. 在第二季度將其在 Vertex Pharmaceuticals 的持股增加了 1.9%。Kovack Advisors Inc. 目前持有 1,280 股該製藥公司的股票，價值 570,000 美元，此前在該期間又購買了 24 股。Newman Dignan  Sheerar Inc. 在第二季度將其在 Vertex Pharmaceuticals 的股份增加了 3.3%。Newman Dignan  Sheerar Inc. 目前持有 786 股該製藥公司的股票，價值 350,000 美元，此前在上個季度又購買了 25 股。Eastern Bank 在第二季度將其在 Vertex Pharmaceuticals 的持股增加了 1.6%。Eastern Bank 目前持有 1,635 股該製藥公司的股票，價值 728,000 美元，此前在該期間又收購了 25 股。最後，Washington Trust Advisors Inc. 在第二季度將其在 Vertex Pharmaceuticals 的股份增加了 8.4%。Washington Trust Advisors Inc. 目前持有 323 股該製藥公司的股票，價值 144,000 美元，此前在上個季度又收購了 25 股。90.96% 的股票由對沖基金和其他機構投資者持有。</p>
</div><p>Get <strong>Vertex Pharmaceuticals</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>Vertex Pharmaceuticals</strong> 的提醒：</p>
</div><h2>Insiders Place Their Bets</h2>
<div class="lb-trans"><h2>內部人士下注</h2>
</div><p>In other Vertex Pharmaceuticals news, EVP Charles F. Wagner, Jr. sold 14,000 shares of the firm's stock in a transaction dated Wednesday, December 3rd. The stock was sold at an average price of $456.00, for a total transaction of $6,384,000.00. Following the sale, the executive vice president owned 37,725 shares in the company, valued at $17,202,600. This trade represents a 27.07% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Chairman Jeffrey M. Leiden sold 63,781 shares of the company's stock in a transaction dated Wednesday, December 3rd. The stock was sold at an average price of $449.20, for a total value of $28,650,425.20. Following the completion of the transaction, the chairman owned 24,026 shares of the company's stock, valued at $10,792,479.20. The trade was a 72.64% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last three months, insiders sold 151,073 shares of company stock worth $67,326,816. 0.20% of the stock is owned by insiders.</p>
<div class="lb-trans"><p>在其他 Vertex Pharmaceuticals 的新聞中，執行副總裁 Charles F. Wagner, Jr. 於 12 月 3 日星期三出售了 14,000 股該公司的股票。股票以平均價格 456.00 美元出售，總交易額為 6,384,000.00 美元。出售後，該執行副總裁在公司持有 37,725 股，價值 17,202,600 美元。此交易代表其持股減少了 27.07%。該交易在向 SEC 提交的文件中披露，相關文件可通過此鏈接獲取。此外，董事長 Jeffrey M. Leiden 於 12 月 3 日星期三出售了 63,781 股公司的股票。股票以平均價格 449.20 美元出售，總價值為 28,650,425.20 美元。交易完成後，董事長持有 24,026 股公司的股票，價值 10,792,479.20 美元。該交易使其持股減少了 72.64%。該銷售的 SEC 文件提供了更多信息。在過去三個月中，內部人士出售了 151,073 股公司股票，價值 67,326,816 美元。0.20% 的股票由內部人士持有。</p>
</div><h2>Vertex Pharmaceuticals Trading Down 1.2%</h2>
<div class="lb-trans"><h2>Vertex Pharmaceuticals 股價下跌 1.2%</h2>
</div><ul>
<li>Best Biotech Stocks to Buy in 2025</li>
</ul>
<div class="lb-trans"><ul>
<li>2025 年最佳生物技術股票</li>
</ul>
</div><p>VRTX stock opened at $449.52 on Thursday. The company's 50 day moving average is $429.02 and its 200 day moving average is $425.79. The stock has a market cap of $114.05 billion, a price-to-earnings ratio of 31.70 and a beta of 0.32. Vertex Pharmaceuticals Incorporated has a 1-year low of $362.50 and a 1-year high of $519.68.</p>
<div class="lb-trans"><p>VRTX 股票在星期四開盤價為 449.52 美元。該公司的 50 日移動平均線為 429.02 美元，200 日移動平均線為 425.79 美元。該股票的市值為 1,140.5 億美元，市盈率為 31.70，貝塔值為 0.32。Vertex Pharmaceuticals Incorporated 的 1 年最低價為 362.50 美元，1 年最高價為 519.68 美元。</p>
</div><p>Vertex Pharmaceuticals (NASDAQ:VRTX - Get Free Report) last released its quarterly earnings results on Monday, November 3rd. The pharmaceutical company reported $4.80 EPS for the quarter, topping analysts' consensus estimates of $4.58 by $0.22. The business had revenue of $3.08 billion during the quarter, compared to analysts' expectations of $3.05 billion. Vertex Pharmaceuticals had a net margin of 31.35% and a return on equity of 23.51%. The business's quarterly revenue was up 11.0% compared to the same quarter last year. During the same quarter in the previous year, the company earned $4.38 EPS. As a group, sell-side analysts forecast that Vertex Pharmaceuticals Incorporated will post 15.63 EPS for the current fiscal year.</p>
<div class="lb-trans"><p>Vertex Pharmaceuticals (NASDAQ:VRTX - 獲取免費報告) 最近於 11 月 3 日星期一發布了季度財報。該製藥公司報告季度每股收益為 4.80 美元，超出分析師一致預期的 4.58 美元，超出幅度為 0.22 美元。該業務在季度內的收入為 30.8 億美元，而分析師預期為 30.5 億美元。Vertex Pharmaceuticals 的淨利潤率為 31.35%，股本回報率為 23.51%。該業務的季度收入較去年同期增長了 11.0%。在去年同期，該公司每股收益為 4.38 美元。作為一個整體，賣方分析師預測 Vertex Pharmaceuticals Incorporated 在當前財政年度將發佈 15.63 美元的每股收益。</p>
</div><h2>Analyst Ratings Changes</h2>
<div class="lb-trans"><h2>分析師評級變動</h2>
</div><ul>
<li>MaxCyte: Building the Future of Cell and Gene Therapy Innovation</li>
</ul>
<div class="lb-trans"><ul>
<li>MaxCyte：構建細胞和基因治療創新的未來</li>
</ul>
</div><p>Several equities analysts have recently weighed in on VRTX shares. Royal Bank Of Canada reduced their price target on Vertex Pharmaceuticals from $423.00 to $415.00 and set a &#34;sector perform&#34; rating for the company in a research report on Tuesday, November 4th. JPMorgan Chase &amp; Co. lifted their target price on Vertex Pharmaceuticals from $517.00 to $530.00 and gave the company an &#34;overweight&#34; rating in a report on Wednesday, October 8th. Weiss Ratings reissued a &#34;hold (c+)&#34; rating on shares of Vertex Pharmaceuticals in a report on Wednesday, October 8th. Citigroup raised their price objective on shares of Vertex Pharmaceuticals from $550.00 to $575.00 and gave the company a &#34;buy&#34; rating in a research report on Thursday, October 2nd. Finally, Wall Street Zen lowered shares of Vertex Pharmaceuticals from a &#34;strong-buy&#34; rating to a &#34;buy&#34; rating in a report on Friday, August 22nd. Three investment analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and ten have issued a Hold rating to the company's stock. Based on data from MarketBeat, the stock has a consensus rating of &#34;Moderate Buy&#34; and an average target price of $498.42.</p>
<div class="lb-trans"><p>幾位股票分析師最近對 VRTX 股票發表了看法。加拿大皇家銀行在 11 月 4 日的研究報告中將 Vertex Pharmaceuticals 的目標價從 423.00 美元下調至 415.00 美元，並對該公司給予了 “行業表現” 評級。摩根大通在 10 月 8 日的報告中將 Vertex Pharmaceuticals 的目標價從 517.00 美元上調至 530.00 美元，並給予該公司 “增持” 評級。Weiss Ratings 在 10 月 8 日的報告中重新發布了對 Vertex Pharmaceuticals 股票的 “持有（c+）” 評級。花旗集團在 10 月 2 日的研究報告中將 Vertex Pharmaceuticals 股票的目標價從 550.00 美元上調至 575.00 美元，並給予該公司 “買入” 評級。最後，華爾街禪在 8 月 22 日的報告中將 Vertex Pharmaceuticals 的評級從 “強烈買入” 下調至 “買入”。三位投資分析師對該股票給予了強烈買入評級，十五位給予了買入評級，十位對該公司的股票給予了持有評級。根據 MarketBeat 的數據，該股票的共識評級為 “適度買入”，平均目標價為 498.42 美元。</p>
</div><p><strong>Get Our Latest Stock Report on VRTX</strong></p>
<div class="lb-trans"><p><strong>獲取我們最新的 VRTX 股票報告</strong></p>
</div><h2>Vertex Pharmaceuticals Company Profile</h2>
<div class="lb-trans"><h2>Vertex Pharmaceuticals 公司簡介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免費報告）</p>
</div><p>Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.</p>
<div class="lb-trans"><p>Vertex Pharmaceuticals Incorporated 是一家生物技術公司，專注於開發和商業化治療囊性纖維化（CF）的療法。它為至少有一個 F508del 突變、年齡在 2 歲或以上的 CF 患者銷售 TRIKAFTA/KAFTRIO；為年齡在 6 歲或以上的 CF 患者銷售 SYMDEKO/SYMKEVI；為 1 歲或以上的 CF 患者銷售 ORKAMBI；以及為 1 歲或以上的 CF 患者銷售 KALYDECO，適用於 ivacaftor 治療。</p>
</div><h2>Recommended Stories</h2>
<div class="lb-trans"><h2>推薦故事</h2>
</div><ul>
<li>Five stocks we like better than Vertex Pharmaceuticals</li>
<li>What Are the FAANG Stocks and Are They Good Investments?</li>
<li>Post 35% Surge, Analysts Eye More Upside in Copper Giant Freeport</li>
<li>Energy and Oil Stocks Explained</li>
<li>Why a SpaceX IPO Could Be a Major Catalyst for GOOGL Stock</li>
<li>Market Cap Calculator: How to Calculate Market Cap</li>
<li>Can Upwork Maintain Its Comeback? Reasons to Be Bullish and Bearish</li>
</ul>
<div class="lb-trans"><ul>
<li>我們更看好的五隻股票，勝過 Vertex Pharmaceuticals</li>
<li>FAANG 股票是什麼？它們是好的投資嗎？</li>
<li>在上漲 35% 後，分析師關注銅業巨頭 Freeport 的更多上漲空間</li>
<li>能源和石油股票解析</li>
<li>為什麼 SpaceX 的 IPO 可能成為 GOOGL 股票的主要催化劑</li>
<li>市值計算器：如何計算市值</li>
<li>Upwork 能否維持復甦？看漲和看跌的理由</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VlJUWA" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NASDAQ&amp;Symbol=VRTX"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，旨在為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Vertex Pharmaceuticals Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資$1,000 在 Vertex Pharmaceuticals 嗎？</h2>
</div><p>Before you consider Vertex Pharmaceuticals, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮 Vertex Pharmaceuticals 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Vertex Pharmaceuticals wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄建議客户現在購買的股票，以便在更廣泛的市場注意到之前……而 Vertex Pharmaceuticals 並不在名單上。</p>
</div><p>While Vertex Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Vertex Pharmaceuticals 目前在分析師中獲得了中等買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

Thurston Springer Miller Herd & Titak Inc.出售了福泰製藥公司（Vertex Pharmaceuticals Incorporated）的 2,487 股股票，股票代碼為 VRTX